BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Sep 29, 2017
Financial News

Ascendis and Catalent price follow-ons

Catalent Inc. (NYSE:CTLT) and Ascendis Pharma A/S (NASDAQ:ASND) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Sept. 27 through the sale of 3.8 million ADSs at $35.50 in a...
BC Extra | Sep 27, 2017
Financial News

Follow-on roundup: Ascendis, Catalent

Ascendis Pharma A/S (NASDAQ:ASND) and Catalent Inc. (NYSE:CTLT) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Wednesday through the sale of 3.8 million ADSs at $35.50 in a follow-on...
BC Extra | Sep 22, 2017
Financial News

Versartis plummets on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) lost $18.93 (88%) to $2.67 on Friday after announcing after market close Thursday that somavaratan (VRS-317) missed the primary endpoint in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency...
BC Week In Review | Sep 22, 2017
Clinical News

Versartis' somavaratan misses in Phase III for pediatric GHD

Versartis Inc. (NASDAQ:VSAR) said somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency (GHD). In the intent-to-treat (ITT) population, twice-monthly subcutaneous...
BC Extra | Sep 22, 2017
Clinical News

Versartis falls on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) plummeted $18.20 (84%) to $3.40 in after-hours trading Thursday after reporting that somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Extra | Dec 30, 2016
Clinical News

Opko GHD candidate fails Phase III study in adults

Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) on Friday reported its long-acting human growth hormone (hGH) analog hGH-CTP missed the primary endpoint in a Phase III trial to treat adults with growth hormone deficiency. The study...
BC Week In Review | Aug 15, 2016
Company News

Versartis, Teijin Pharma deal

Versartis granted Teijin exclusive, Japanese rights to develop and commercialize somavaratan , a long-acting recombinant human growth hormone (rhGH) that is in Phase III development to treat growth hormone deficiency. Versartis will receive $40 million up...
Items per page:
1 - 10 of 40